Isoflavones impair anti-PD1 efficacy in breast cancer, regardless of dietary fiber or fecal short-chain fatty acid levels - Takeaways - MDSpire

Isoflavones impair anti-PD1 efficacy in breast cancer, regardless of dietary fiber or fecal short-chain fatty acid levels

  • By

  • Fabia de Oliveira Andrade

  • Kerrie B. Bouker

  • Melike Ozgul-Onal

  • Lu Jin

  • Idalia Cruz

  • William Helferich

  • Audrey Gao

  • Karla Andrade de Oliveira

  • Vivek Verma

  • Christopher Staley

  • Patricia L. Foley

  • Leena Hilakivi-Clarke

  • July 6, 2026

  • 0 min

Share

  • 1

    High-MAC diets increased fecal microbial diversity and SCFA levels compared to low-MAC diets in breast cancer models.

  • 2

    Anti-PD1 treatment was effective in TNBC models with high-MAC or low-MAC diets but was negated by isoflavone inclusion.

  • 3

    In high-MACi-fed mice, anti-PD1 increased exhausted CD8+ T cells, contrasting with its effects in high-MAC-fed mice.

  • 4

    ERα+ tumors showed resistance to anti-PD1, but tamoxifen treatment enhanced sensitivity in both TNBC and ERα+ models.

  • 5

    The study indicates that isoflavones impair the effectiveness of ICB therapies, independent of SCFA levels.

Original Source(s)

Isoflavones impair anti-PD1 efficacy in breast cancer, regardless of dietary fiber or fecal short-chain fatty acid levels

  • by Fabia de Oliveira Andrade, Kerrie B. Bouker, Melike Ozgul-Onal, Lu Jin, Idalia Cruz, William Helferich, Audrey Gao, Karla Andrade de Oliveira, Vivek Verma, Christopher Staley, Patricia L. Foley, Leena Hilakivi-Clarke

  • July 6, 2026

Related Content

A super-elderly patient with distal biliary tract cancer and tumor-associated granuloma: a case report

AI Framework Helps Identify New CAR T Target

A human-in-the-loop AI strategy helped narrow more than 10,000 candidates to a CAR T target now validated in mouse models

  • July 6, 2026

  • 3 min
Cytokine delivery and targeting strategies in pet dogs with cancer: a comparative immuno-oncology approach